Jeet Mahal
Direttore operativo presso JASPER THERAPEUTICS, INC.
Patrimonio netto: 649 234 $ in data 31/05/2024
Profilo
Jeet Mahal is currently the Chief Operating Officer at Jasper Therapeutics, Inc. Prior to this, he held positions at Scios, Inc. as the Director of Business & New Product Development, Johnson & Johnson as the Director of Business & New Product Development, COR Therapeutics, Inc. as a Principal, and Portola Pharmaceuticals LLC as the Vice President of Strategic Marketing.
Mr. Mahal has an MBA from Duke University, a graduate degree from the Illinois Institute of Technology and North Carolina State University, an undergraduate degree from the University of California, Berkeley, and another MBA from The Fuqua School of Business.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 12/06/2024 | 25 009 ( 0.17% ) | 649 234 $ | 31/05/2024 |
Posizioni attive di Jeet Mahal
| Società | Posizione | Inizio |
|---|---|---|
| JASPER THERAPEUTICS, INC. | Direttore operativo | 21/03/2022 |
Precedenti posizioni note di Jeet Mahal
| Società | Posizione | Fine |
|---|---|---|
| PORTOLA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/12/2019 |
| JOHNSON & JOHNSON | Corporate Officer/Principal | 01/09/2008 |
COR Therapeutics, Inc.
 COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | Corporate Officer/Principal | - |
Scios, Inc.
 Scios, Inc. Pharmaceuticals: MajorHealth Technology Scios Inc. developed, manufactured, and commercialized pharmaceuticals for conditions such as cardiovascular and inflammatory diseases. The company was founded in 1981 and was headquartered in Sunnyvale, CA. | Corporate Officer/Principal | - |
Formazione di Jeet Mahal
| University of California, Berkeley | Undergraduate Degree |
| Illinois Institute of Technology | Graduate Degree |
| North Carolina State University | Graduate Degree |
| The Fuqua School of Business | Masters Business Admin |
| Duke University | Masters Business Admin |
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| JASPER THERAPEUTICS, INC. | Finance |
| JOHNSON & JOHNSON | Health Technology |
| Aziende private | 3 |
|---|---|
Portola Pharmaceuticals LLC
 Portola Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Portola Pharmaceuticals, Inc. engaged in the development and commercialization of novel therapeutics in the areas of thrombosis, other hematologic disorders, and inflammation. It offers Andexxa and Bevyxxa medicines. The company was founded by Charles J. Homcy and David R. Philips on September 2, 2003 and is headquartered in South San Francisco, CA. | Health Technology |
Scios, Inc.
Scios, Inc. Pharmaceuticals: MajorHealth Technology Scios Inc. developed, manufactured, and commercialized pharmaceuticals for conditions such as cardiovascular and inflammatory diseases. The company was founded in 1981 and was headquartered in Sunnyvale, CA. | Health Technology |
COR Therapeutics, Inc.
COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | Health Technology |
- Borsa valori
- Insiders
- Jeet Mahal
